Next-Gen Data Access for Pharma: How Integrated Data Ecosystems Are Powering Global Pharma Decision-Making

Introduction:

In today’s dynamic pharmaceutical landscape, the need for seamless data access and faster decision-making has made AI-powered, cloud-based solutions a cornerstone of innovation. As a pharma company that works across multiple therapy areas simultaneously, traditional data silos have proven inefficient for providing insights into country-specific disease burden, epidemiology research, and, essentially, market forecasts. To address these challenges, Thelansis developed an AI-enabled cloud platform that transforms how organizations access, analyze, and apply epidemiology and market insights. This case study explores how Thelansis partnered with a global biopharma client to streamline their research processes.

Objective:

A client with a diverse product portfolio sought a centralized, scalable, and Competitive Intelligence system to access reliable epidemiology and disease landscape insights. Our team collaborated with theirs to understand their requirements, based on the product pipeline, lifecycle management priorities, and future interests. Our primary goal was to simplify access to epidemiology and market forecasts across multiple therapeutic areas and geographies, enabling them to support their needs with real-time, high-quality insights.

Approach:

We further customized our proprietary AI-enabled cloud platform, transforming data into a user-friendly technology, and provided access to epidemiology and landscape insights for all prioritized indications. The platform offered intuitive dashboards, data visualization, and exportable reports, ensuring easy integration with the client’s internal systems.

During demo sessions, our team showcased the depth and breadth of epidemiology coverage at a global level, including prevalence, incidence, demographic distributions, severity-wise distribution, diagnosis, prognosis, treatment utilization, patient journey, and emerging therapy.

In the pilot phase, the client’s teams accessed the platform to get real-time research insights. They mentioned that this tool helped them save a significant amount of time and provided 24/7 analyst-like support to address queries, ensuring seamless adoption and confidence in data quality.

Outcome:

  • 60% reduction in time spent gathering and validating disease area landscape data
  • Enhanced decision-making through consistent, validated, and high-quality datasets with visual analytics
  • 5X times faster data processing and report generation


Read more: Next-Gen Data Access for Pharma: How Integrated Data Ecosystems Are Powering Global Pharma Decision-Making


Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more